Summary Cypralis Ltd (Cypralis), formerly Selcia Pharma Ltd is a drug developer that provides discovery and development of therapeutics targeting peptidyl-prolyl isomerases.The company spans its expertise in the development of medicines for degenerative diseases such as acute tissue injury, liver disease, inflammation, and others.
It develops pplases enzymes that are characterized by their ability to catalyze interconversion of cis- and trans- peptidyl-proline bonds in proteins that are able to exert control over target protein structure and functions.Cypralis works in partnership with pharma and biotech companies to develop ppiase inhibitors for acute and chronic diseases.
The company operates in the UK. Cypralis is headquartered in Cambridge, the UK.
Cypralis Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings.The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.
The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope - Financial Deals - Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company’s operations. - Key Employees - A list of the key executives of the company. - Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company.
Reasons to Buy Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements - The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy - The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Our reports have been used by over 10K customers, including:
Colitis - Pipeline Review, H1 2020 Summary The latest Pharmaceutical and Healthcare disease pipeline guide Colitis - Pipeline Review, H1 2020, provides an overview of the Colitis (Gastrointestinal) pipeline landscape. Colitis is swelling (inflammation) of the large intestine (colon). Colitis...
Glycoprotein 41 (gp41) - Pipeline Review, H2 2019 Summary According to the recently published report ’Glycoprotein 41 (gp41) - Pipeline Review, H2 2019’; Glycoprotein 41 (gp41) pipeline Target constitutes close to 20 molecules. Out of which approximately 12 molecules are developed by companies and...
Gamma Secretase (EC 3.4.23.) - Pipeline Review, H2 2019 Summary Gamma Secretase (EC 3.4.23.) pipeline Target constitutes close to 21 molecules. Out of which approximately 18 molecules are developed by companies and remaining by the universities/institutes. The latest report Gamma Secretase (EC 3.4.23.)...
Human Papillomavirus Protein E7 (E7) - Pipeline Review, H2 2019 Summary Human Papillomavirus Protein E7 (E7) pipeline Target constitutes close to 44 molecules. Out of which approximately 29 molecules are developed by companies and remaining by the universities/institutes. The latest report Human...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.